1. Home
  2. XBIT vs PYXS Comparison

XBIT vs PYXS Comparison

Compare XBIT & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XBiotech Inc.

XBIT

XBiotech Inc.

HOLD

Current Price

$2.43

Market Cap

75.0M

Sector

Health Care

ML Signal

HOLD

Logo Pyxis Oncology Inc.

PYXS

Pyxis Oncology Inc.

HOLD

Current Price

$1.70

Market Cap

82.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XBIT
PYXS
Founded
2005
2018
Country
United States
United States
Employees
85
N/A
Industry
Pharmaceuticals and Biotechnology
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
75.0M
82.3M
IPO Year
2015
2021

Fundamental Metrics

Financial Performance
Metric
XBIT
PYXS
Price
$2.43
$1.70
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$7.00
AVG Volume (30 Days)
42.9K
340.8K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
3.03
EPS
N/A
N/A
Revenue
N/A
$13,858,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$7,043.98
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.09
$0.92
52 Week High
$3.61
$5.55

Technical Indicators

Market Signals
Indicator
XBIT
PYXS
Relative Strength Index (RSI) 56.48 60.11
Support Level $2.15 $1.28
Resistance Level $2.46 $1.69
Average True Range (ATR) 0.07 0.11
MACD 0.02 0.03
Stochastic Oscillator 70.83 71.55

Price Performance

Historical Comparison
XBIT
PYXS

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

About PYXS Pyxis Oncology Inc.

Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.

Share on Social Networks: